Feature|Videos|July 23, 2025
Rethinking Market Strategy within a Patient-Centric Era
A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and future drug development and market access efforts.
Advertisement
Episodes in this series
As the series closes, the panel reflects on an often underrepresented but crucial stakeholder: the patient. The discussion underscores the need for a more patient-centered market access strategy—one that incorporates health equity, diagnostic and treatment journey support, and clearer communication around cost and adherence.
Key discussion topics include:
- How social determinants of health (SDOH) shape real-world treatment access.
- The growing need for payer transparency and patient trust in the marketplace.
- Strategies to engage patients early in development to ensure success.
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
The Battle to Own the GLP-1 Patient Journey
3
Novo Announces Drug Discovery Collaboration with Anthropic
4
Understanding the Latest with MFN Pricing and What It Means to Pharma
5